Karo Bio: European Patent Strengthens Project for Treatment of Atherosclerosis HUDDINGE, Sweden, April 16, 2002 (PRIMEZONE) -- Karo Bio has received a European patent for the LXR beta-receptor, which is a new important drug discovery target for treatment of...

Karo Bio: Update in Program to Develop Treatment for Obesity HUDDINGE, Sweden, March 27, 2002 (PRIMEZONE) -- Karo Bio today announced that Bristol-Myers Squibb Company has discontinued development of the first thyroid hormone receptor modulator for treatment...

Karo Bio Receives Award for Prostate Cancer Research HUDDINGE, Sweden, March 12, 2002 (PRIMEZONE) -- Karo Bio USA, Inc. has received a three year award from the Department of the Army* for drug discovery in prostate cancer. The project applies the...

Karo Bio: Full Year Report 2001 - Quarterly Report, October-December 2001 (with link) HUDDINGE, Sweden, Feb. 8, 2002 (PRIMEZONE) -- Karo Bio: -- American Home Products became strategic partner for atherosclerosis. The agreement may bring Karo Bio MUSD 100 in revenues...

Karo Bio and GPC Biotech Successfully Develop Ten Assays for Novel Anibacterial Targets MUNICH, Germany, Feb. 6, 2002 (PRIMEZONE) -- Karo Bio USA, Inc., a wholly owned subsidiary of Karo Bio AB, and GPC Biotech AG (Frankfurt Stock Exchange: GPC) today announced that their technology...